NCT00102024终止1 期
A Phase I/II, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Single Dose 90Y-Labeled IDEC-159, Humanized, Domain Deleted, Anti TAG-72 Monoclonal Antibody, in Subjects With Metastatic Colorectal Adenocarcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Biogen
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- To characterize the safety profile and determine the MTD of 90Y-IDEC-159 in subjects with metastatic colorectal cancer.
研究概览
简要总结
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign an Institutional Review Board (IRB)-approved informed consent.
- •Metastatic colorectal adenocarcinoma that has been pathologically confirmed following failed response or relapse while on or following fluoropyrimidine, irinotecan, and oxaliplatin chemotherapy. (Prior therapy with cetuximab is recommended if the tumors are epidermal growth factor receptor [EGFR] positive.)
- •Age 18 or above.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or
- •Recovered to baseline toxicity from any significant toxicity associated with prior surgery, chemotherapy, biological therapy, or investigational drug.
- •Adequate bone marrow reserve (absolute neutrophil count > 1500 cells/mm3, platelet count > 125,000 cells/mm3, hemoglobin concentration ≥ 10 g/dL).
- •Radiographically measurable disease (RECIST criteria).
- •Life expectancy of at least 3 months.
- •Male and female subjects of reproductive potential must agree to follow accepted birth control methods, as determined by the investigator, during treatment and for 12 months after completion of treatment.
排除标准
- •Prior radioimmunotherapy.
- •Known presence of central nervous system (CNS) metastasis.
- •Any lesion > 7.5 cm.
- •Total bilirubin > 2.0 mg/dL.
- •Total creatinine > 2.0 mg/dL.
- •AST and ALT > 2.5 times upper limit of normal (ULN), if metastases to the liver > 5 times ULN.
- •Presence of a second primary malignancy requiring active treatment (except for hormonal therapy).
- •Serious non-malignant disease or infection that, in the opinion of either the investigator or sponsor, would compromise protocol objectives.
- •History of external beam radiation therapy to > 25% of active bone marrow.
- •History of bone marrow or stem cell transplant.
- •History of granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) therapy within 2 weeks before Study Day
- •History of pegylated G-CSF therapy within 4 weeks before Study Day
- •History of major surgery, other than diagnostic surgery, within 4 weeks of Study Day
- •History of receiving investigational product within 4 weeks before Study Day 1 or long term toxicity from a previous investigational therapy.
- •Known history of HIV or AIDS.
- •Concurrent systemic corticosteroid therapy or other immunosuppressive agents, unless for the treatment of computed tomography (CT) dye allergy reactions.
- •Pregnant or lactating female.
结局指标
主要结局
To characterize the safety profile and determine the MTD of 90Y-IDEC-159 in subjects with metastatic colorectal cancer.
次要结局
- To evaluate activity; blood, normal organ, and tumor dosimetry; the immunogenicity and pharmacokinetics of 90Y-IDEC-159; and its effect on soluble TAG-72 (sTAG-72) levels.
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)Colorectal Cancer MetastaticNCT06634875Buzzard Pharmaceuticals20
已完成
1 期
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdvanced/Metastatic Solid TumorsNCT04501276Adagene Inc72
已完成
1 期
A Study of AGEN2034 in Advanced Tumors and Cervical CancerAdvanced CancerCervical CancerNCT03104699Agenus Inc.211
终止
1 期
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal CancerMetastatic Colorectal CarcinomaNCT01937715Pfizer18
终止
1 期
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid TumorsTumorsNCT00105170Biogen13